Form 4: Glaukos COO Sells 19,340 Shares in Pre-Planned Sale

Glaukos Corporation's President & COO, Joseph E. Gilliam, reported the sale of 19,340 shares of common stock at $90 per share, executed under a Rule 10b5-1 plan.

Summary

• Joseph E. Gilliam, President & COO and a Director of Glaukos Corporation (GKOS), reported a transaction on November 18, 2025.
• Gilliam disposed of 19,340 shares of Glaukos Common Stock at a price of $90 per share.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer, intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• Following this transaction, Gilliam beneficially owns 92,366 shares of Glaukos Common Stock.
• The beneficially owned shares include 62,605 restricted stock units (RSUs) that have not yet vested or been delivered to the Reporting Person.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly negative. While an insider sale can be viewed negatively, the disclosure that it was executed under a Rule 10b5-1 plan mitigates concerns that it was based on new, non-public information, thus moving the sentiment closer to neutral.

Positives

• The sale was conducted under a Rule 10b5-1 plan, indicating it was pre-scheduled and not based on immediate, non-public information, which can mitigate negative perceptions of insider selling.

Negatives

• A high-ranking executive selling a significant number of shares (19,340 shares) could be perceived by some investors as a signal of reduced confidence, even if pre-planned.
• A substantial portion of the remaining beneficial ownership (62,605 out of 92,366 shares) consists of unvested restricted stock units, which are not immediately liquid.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends. Insider sales are a common occurrence in publicly traded companies, often for personal financial planning, and are closely watched by investors for potential signals about management's confidence in the company's future.

Stakeholder Impact

• Shareholders may interpret the insider sale as a signal, potentially influencing their perception of management's confidence or the stock's valuation, although the 10b5-1 plan mitigates this impact.

Key Dates

Keywords

Glaukos, GKOS, Insider Sale, Form 4, Joseph E Gilliam, Stock Transaction, 10b5-1 Plan, Medical Devices, Ophthalmology